Showing results (541-550 of 645) with videos related to

Sort By:
Pageof 65
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|July 22, 2005
A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipientsGary L Davis, David R Nelson, Norah Terrault, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 7, 2011
Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3Samir R Shah, Keyur Patel, Patrick Marcellin, et al.
The Journal of Biological Chemistry|January 21, 2014
Structure and biochemical properties of the alkene producing cytochrome P450 OleTJE (CYP152L1) from the Jeotgalicoccus sp. 8456 bacteriumJames Belcher, Kirsty J McLean, Sarah Matthews, et al.
Hepatology (Baltimore, Md.)|December 25, 2004
Reconstitution of hepatitis C virus-specific T-cellmediated immunity after liver transplantationScott J Weston, Rachel L Leistikow, K Rajender Reddy, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|November 9, 2002
Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis CRoberto J Firpi, Manal F Abdelmalek, Consuelo Soldevila-Pico, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 29, 2015
HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscapeNancy Reau, Michael W Fried, David R Nelson, et al.
Hepatology (Baltimore, Md.)|August 13, 2008
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirinMichael W Fried, Donald M Jensen, Maribel Rodriguez-Torres, et al.
The Journal of Infectious Diseases|November 26, 2015
L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B SubstitutionsEvguenia S Svarovskaia, Edward Gane, Hadas Dvory-Sobol, et al.
The New England Journal of Medicine|April 12, 2014
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirinJordan J Feld, Kris V Kowdley, Eoin Coakley, et al.
The Lancet. Gastroenterology & Hepatology|June 4, 2017
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trialAnnette Bruchfeld, David Roth, Paul Martin, et al.
Pageof 65